Aardvark Therapeutics, Inc. (NASDAQ:AARD) Receives Consensus Rating of “Hold” from Analysts

Posted by Brenda Bartman on Jun 22nd, 2026

Aardvark Therapeutics, Inc. (NASDAQ:AARD – Get Free Report) has been assigned an average rating of “Hold” from the thirteen analysts that are presently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $19.70.

Several research analysts recently issued reports on the stock. Oppenheimer reduced their price target on shares of Aardvark Therapeutics from $35.00 to $21.00 and set an “outperform” rating on the stock in a research report on Monday, March 2nd. B. Riley Financial dropped their target price on shares of Aardvark Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research note on Friday, May 15th. BTIG Research lowered shares of Aardvark Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 15th. Weiss Ratings cut shares of Aardvark Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 27th. Finally, HC Wainwright reissued a “neutral” rating on shares of Aardvark Therapeutics in a report on Monday, March 2nd.

Get Our Latest Analysis on Aardvark Therapeutics

Institutional Investors Weigh In On Aardvark Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Aardvark Therapeutics in the second quarter valued at about $42,000. China Universal Asset Management Co. Ltd. bought a new stake in Aardvark Therapeutics during the 4th quarter worth about $47,000. Persistent Asset Partners Ltd acquired a new position in Aardvark Therapeutics during the 4th quarter valued at about $56,000. New York State Common Retirement Fund acquired a new position in Aardvark Therapeutics during the 2nd quarter valued at about $99,000. Finally, MetLife Investment Management LLC bought a new position in shares of Aardvark Therapeutics in the 4th quarter valued at about $102,000.

Aardvark Therapeutics Price Performance

AARD stock opened at $3.94 on Monday. The business has a fifty day moving average price of $4.66 and a 200 day moving average price of $8.66. Aardvark Therapeutics has a fifty-two week low of $3.35 and a fifty-two week high of $17.94. The stock has a market capitalization of $85.95 million, a price-to-earnings ratio of -1.23 and a beta of 4.50.

Aardvark Therapeutics (NASDAQ:AARD – Get Free Report) last announced its earnings results on Thursday, May 7th. The company reported ($0.99) EPS for the quarter. On average, equities analysts expect that Aardvark Therapeutics will post -3.46 earnings per share for the current fiscal year.

About Aardvark Therapeutics

(Get Free Report)

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.